Cytokinetics

YTD

ALL

Trade Cytokinetics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CYTK

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility.

CEO

Robert I. Blum

CEORobert I. Blum

Employees

673

Employees673

Headquarters

South San Francisco, California

HeadquartersSouth San Francisco, California

Founded

1997

Founded1997

Employees

673

Employees673

CYTK Key Statistics

Market cap

9.63B

Market cap9.63B

Price-Earnings ratio

-11.27

Price-Earnings ratio-11.27

Dividend yield

—

Dividend yield—

Average volume

1.64M

Average volume1.64M

High today

$81.05

High today$81.05

Low today

$76.96

Low today$76.96

Open price

$80.32

Open price$80.32

Volume

1.58M

Volume1.58M

52 Week high

$88.31

52 Week high$88.31

52 Week low

$32.89

52 Week low$32.89

Stock Snapshot

With a market cap of 9.63B, Cytokinetics(CYTK) trades at $77.13. The stock has a price-to-earnings ratio of -11.27.

During the trading session on 2026-08-01, Cytokinetics(CYTK) shares reached a daily high of $81.05 and a low of $76.96. At a current price of $77.13, the stock is +0.2% higher than the low and still -4.8% under the high.

Trading activity shows a volume of 1.58M, compared to an average daily volume of 1.64M.

Over the past 52 weeks, Cytokinetics(CYTK) stock has traded between a high of $88.31 and a low of $32.89.

CYTK News

TipRanks 1d

Top Cytokinetics Executive Makes Eye-Catching Move With Insider Stock Sale

New insider activity at Cytokinetics ( (CYTK) ) has taken place on July 30, 2026. Claim 55% Off TipRanks Unlock powerful investing tools with TipRanks Premium t...

Simply Wall St 1d

The Bull Case For Cytokinetics Could Change Following UK NHS Backing Of Aficamten Access - simplywall.st

...

TipRanks 2d

Cytokinetics announces MHRA authorization for Myqorzo

Cytokinetics (CYTK) announced that the Medicines and Healthcare products Regulatory Agency has granted Myqorzo a marketing authorisation across the United Kingd...

Analyst ratings

91%

of 22 ratings

Buy

90.9%

Hold

9.1%

Sell

More CYTK News

Simply Wall St 4d

Is Cytokinetics Cheap Or Has Its Cardiac Growth Story Already Been Priced In?

Advertisement Recent performance snapshot Cytokinetics (CYTK) has drawn investor attention after recent trading, with the stock last closing at US$80.62. Retu...

People also own

Based on the portfolios of people who own CYTK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.